An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study LEUKEMIA LYMPHOMA
Lack of the Histone Deacetylase SIRT1 Leads to Protection against Endoplasmic Reticulum Stress through the Upregulation of Heat Shock Proteins Int J Mol Sci
T-TAS(®) 01 as a new tool for the evaluation of hemostasis in thrombocytopenic patients after platelet transfusion BLOOD TRANSFUS-ITALY
Loss of the epithelial marker CDX1 predicts poor prognosis in early-stage CRC patients BBA-MOL CELL RES
Author Correction: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA SCI REP-UK
Structural Stabilization of Clinically Oriented Oligomeric Proteins During their Transit through Synthetic Secretory Amyloids ADV SCI
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study CL LYMPH MYELOM LEUK
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment CL LYMPH MYELOM LEUK
DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study BRIT J HAEMATOL
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022 EClinicalMedicine